Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of mirikizumab in moderate to severe ulcerative colitis
2015-003123-57Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing Mirikizumab with Placebo (2 arms). Primary endpoint: Clinical remission at Week 12. Started Oct 2015; status: completed.
02
Drugs
mirikizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2015-003123-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003123-57.